跳至主要内容
临床试验/JPRN-UMIN000003040
JPRN-UMIN000003040已完成未知

Randomized comparison of Sequential therapies with Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma - CROSS-J-RCC

Yamagata University Faculty of Medicine0 个研究点目标入组 120 人开始时间: 2010年1月15日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) History of any other malignancy 2) Central nervous system metastases. However, patients who remain asymptomatic, have no new or enlarging lesion in the CNS within 6 months of enrollment in this study, and require no corticosteroids may be enrolled. 3) History of cardiac infarction, unstable angina, congestive heart failure, or symptomatic peripheral vascular disease within 12 months of enrollment 4) History of cerebrovascular disorder including transient ischemic attack (TIA) 5) Pregnancy or possible pregnancy at any time during the study 6) Ongoing grade 2 adverse event prior treatment 7) Prior treatment with any anticancer therapy including cytokine therapy such as interferon-alpha and interleukin-2 8) Prior treatment with mTOR inhibitor 9) Prior treatment with sunitinib or sorafenib 10) Treatment with an test drug in a clinical research within 4 weeks of enrollment in this study

研究者

发起方
Yamagata University Faculty of Medicine

相似试验